The long-term goal of the Prevention, Control, and Disparities (PCD) Program is to study how the research findings of basic, epidemiologic, and clinical research have been or should be disseminated and applied in real life. To achieve this end, the following Specific Goals will be pursued: 1. Tobacco control - We focus on the reduction of the use and ill effects of tobacco both within the community and by individuals through the use of pharmacologic and behavioral approaches to smoking cessation, understanding the root causes of addiction, and the study of screening for lung cancer in those who have smoked;2. Chemoprevention / carcinogenesis - We pursue both in vitro studies of mechanisms for the development of chemopreventive agents and their testing in phase 1-3 clinical trials;3. Disparities in the medically underserved - In this aim, we study and suggest interventions for disparities in cancer outcomes based on age, race/ethnicity, income, etc.;and 4. Quality of care / health outcomes - We study patterns and quality of cancer care, and the impact of alterations in care on outcomes. The PCD Program consists of 40 members (31 full members, 5 clinical mebers, and 4 associate members) from 15 departments among 6 schools within Columbia University, as well as faculty from the Weill Cornell School of Medicine and Long Island University. The Program is supported by large program project grants, including a Breast Cancer Center of Excellence grant to study racial disparities in breast cancer treatment and a U54 Cancer Center/Minority Serving Institution Collaborative Partnership with Long Island University. For the last budget year of the grant (July 1, 2006 - June 30, 2007), the PCD Program received a total of $14.1M (direct costs) in cancer-relevant grant support, including $2.9M (direct costs) in NCI funding, $9.9M (direct costs) in other cancer-related peer-reviewed funding, and $1.3M (direct costs) in cancer-related non-peer-reviewed funding. The total number of publications since the previous submission (i.e., 2003- present) was 368 of which 11.4% were intra-programmatic and 33.2% inter-programmatic. Thus, the Program's strengths in the study of racial/ethnic disparities, as well as in survivorship and health outcomes research, have become significant and interactive with other programs in the Cancer Center, including the Breast Program, Cancer Epidemiology Program, and others.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013696-39
Application #
8375765
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
39
Fiscal Year
2012
Total Cost
$30,166
Indirect Cost
$11,436
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Villasante, A; Sakaguchi, K; Kim, J et al. (2017) Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma. Theranostics 7:4099-4117
Ma, Kevin K; Lin, James; Boudreault, Katherine et al. (2017) PHENOTYPING CHOROIDEREMIA AND ITS CARRIER STATE WITH MULTIMODAL IMAGING TECHNIQUES. Retin Cases Brief Rep 11 Suppl 1:S178-S181
Kampers, Johanna; Orjuela-Grimm, Manuela; Schober, Tilmann et al. (2017) Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules. Leuk Lymphoma 58:633-638
Cabral, Thiago; DiCarlo, James E; Justus, Sally et al. (2017) CRISPR applications in ophthalmologic genome surgery. Curr Opin Ophthalmol 28:252-259
Velez, Gabriel; Bassuk, Alexander G; Colgan, Diana et al. (2017) Therapeutic drug repositioning using personalized proteomics of liquid biopsies. JCI Insight 2:
Dutta, Aditya; Panja, Sukanya; Virk, Renu K et al. (2017) Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5?-reductase Inhibition. Eur Urol 72:499-506
Chiang, Wei-Chieh; Chan, Priscilla; Wissinger, Bernd et al. (2017) Achromatopsia mutations target sequential steps of ATF6 activation. Proc Natl Acad Sci U S A 114:400-405
Marks, Lianna J; Oberg, Jennifer A; Pendrick, Danielle et al. (2017) Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience. Front Pediatr 5:265
Kanner, Scott A; Morgenstern, Travis; Colecraft, Henry M (2017) Sculpting ion channel functional expression with engineered ubiquitin ligases. Elife 6:
Wang, Tian; Tsang, Stephen H; Chen, Jeannie (2017) Two pathways of rod photoreceptor cell death induced by elevated cGMP. Hum Mol Genet 26:2299-2306

Showing the most recent 10 out of 263 publications